Reports Q1 revenue $38.9M, consensus $34.38M. Cash, cash equivalents, and investments, excluding short- and long-term restricted cash, at March 31 totaled $874.9M, compared to $772.3M at December 31, 2022. "PacBio is off to a strong start this year with record quarterly revenue. The Revio launch is exceeding our expectations with our customers achieving performance above our specifications for the system," said Christian Henry, President and CEO. "We’ve shipped to dozens of customers worldwide who’ve shared their excitement for deploying Revio’s paradigm-changing throughput and economics. Strong customer demand continued in the first quarter and we ended Q1 with our second consecutive quarter of record backlog."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- PacBio Announces Record Revenue in First Quarter 2023
- PACB Upcoming Earnings Report: What to Expect?
- Pacific Biosciences upgraded to Outperform from Market Perform at TD Cowen
- Pacific Biosciences announces new workflows developed with Corteva
- Pacific Biosciences begins commercial shipment of Revio sequencing systems